Treatment introduction
Endoscopic radiofrequency ablation (RFA, Halo® ablation system) was cleared by the US Food and Drug Administration (FDA) in 2001 under the indications of treating oesophagal diseases. It was also cleared for application by Taiwan's Ministry of Health and Welfare in 2009.
The endoscopic RFA systems have two different types of electrodes, one is circular Halo® 360 and the other is focal Halo® 90.
With its specification, the charged electrode can evenly cauterize the oesophagal mucosa to the depth of less than 0.1 cm. Due to its evenly distributed energy, over-burn has been minimized, which results in decreasing the risks of oesophagal perforation or/and postoperative stricture.
During the procedure, physicians only need to place a special electrode plate on the targeted oesophagal lesion, then have it charged, and then easily harvest the cauterized segment of the diseased oesophagus.
Features
EDHG has used this technique to treat patients with early-stage oesophagal cancers since 2010. Without a doubt, we are the leading expert for early oesophagal cancer treatment in Taiwan. Our experience in treating early oesophagal squamous cell carcinomas is exceptional across the world.
EDHG has also participated in domestic as well as international gastrointestinal societies where we have shared our experience with other medical professionals.
The clinical results on the treatment of an oversized (i.e. greater than 10 centimetres) oesophagal squamous cell carcinomas were also published in many world-renowned medical periodicals.